| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes. | Leuk Res | 2011 | 0.79 |
| 2 | Cardiovascular adverse events complicating the administration of rituximab: report of two cases. | Tumori | 2014 | 0.76 |